|
Camelo-Castillo A, Rivera-Caravaca JM, Orenes-Pinero E, Ramirez-Macias I, Roldan V, Lip GYH, Marin F. Gut Microbiota and the Quality of Oral Anticoagulation in Vitamin K Antagonists Users: A Review of Potential Implications. J Clin Med. 2021 Feb 11;10(4):715. doi: 10.3390/jcm10040715. PubMed PMID: 33670220; PubMed Central PMCID: PMC7916955.
AÑO: 2021; IF: 4.964
|
33670220
|
Ramirez-Macias I, Orenes-Pinero E, Camelo-Castillo A, Rivera-Caravaca JM, Lopez-Garcia C, Marin F. Novel insights in the relationship of gut microbiota and coronary artery diseases. Crit Rev Food Sci Nutr. 2022;62(14):3738-3750. doi: 10.1080/10408398.2020.1868397. Epub 2021 Jan 5. PubMed PMID: 33399007.
AÑO: 2022; IF: 10.2
|
|
Rivera-Caravaca JM, Badimon L, Ferreira-Gonzalez I, Gomez-Doblas JJ, Roca-Luque I, Lekuona I, Jimenez-Candil J, Rodriguez-Padial L, Gonzalez-Juanatey C, Calvo-Jambrina R, Facila L, Ruiz-Ortiz M, Anguita M, Marin F. Variables affecting the quality of anticoagulation in atrial fibrillation patients newly initiating vitamin K antagonists: insights from the national and multicentre SULTAN registry. Europace. 2022 Jan 4;24(1):4-11. doi: 10.1093/europace/euab131. PubMed PMID: 34115857.
AÑO: 2022; IF: 6.1
|
|
Ding WY, Rivera-Caravaca JM, Marin F, Li G, Roldan V, Lip GYH. Number needed to treat for net effect of anticoagulation in atrial fibrillation: Real-world vs. clinical-trial evidence. Br J Clin Pharmacol. 2022 Jan;88(1):282-289. doi: 10.1111/bcp.14961. Epub 2021 Jul 13. PubMed PMID: 34192808.
AÑO: 2022; IF: 3.4
|
|
Rivera-Caravaca JM, Buckley BJR, Harrison SL, Fazio-Eynullayeva E, Underhill P, Marin F, Lip GYH. Direct-acting oral anticoagulants use prior to COVID-19 diagnosis and associations with 30-day clinical outcomes. Thromb Res. 2021 Sep;205:1-7. doi: 10.1016/j.thromres.2021.06.014. Epub 2021 Jun 27. PubMed PMID: 34218058; PubMed Central PMCID: PMC8236305.
AÑO: 2021; IF: 10.407
|